Drug Development
FDA takes steps to reduce animal testing requirements for monoclonal antibodies
Animal testing requirements for monoclonal antibodies and other medications will be “reduced, refined or potentially replaced” in favor of other approaches, including artificial intelligence, according to a recent announcement from the FDA.
ASH sickle cell disease research priorities address pain, organ dysfunction, drug development
American Society of Hematology has issued new sickle cell disease research priorities, highlighting seven key focus areas for maximum impact and benefit to patients.
Enhancing Clinical Trial Enrollment with Michel van Harten, MD
In this episode, host Shikha Jain, MD, speaks with Michel van Harten, MD, about creating better information systems for physicians and patients, how shared decision-making can improve drug development and more.
Advocating for Patient Access with Amita Patnaik, MD, FRCPC
In this episode, host Shikha Jain, MD, speaks with Amita Patnaik, MD, FRCPC, about providing patient access to breakthrough drug developments, bringing early phase cancer trials to physicians and more.
Preventing first thrombosis remains top unmet need in antiphospholipid syndrome
SAN DIEGO — Preventing the first thrombosis, and better circumvention of the second, are currently the biggest obstacles in managing antiphospholipid syndrome, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
Physician has dedicated career to improving access to asthma care ‘that people deserve’
When Andrea A. Pappalardo, MD, FAAAAI, FACAAI, became an allergist, she discovered how difficult it was for many people in her community to access asthma and allergy care, which motivated her to find ways to reach those who needed it.
Eyenovia, SGN Nanopharma to develop treatment for dry eye disease
Eyenovia and SGN Nanopharma have announced a collaboration agreement to develop a new drug-device combination product for chronic dry eye disease.
Breast Cancer Drug Development with Komal Jhaveri, MD
In this episode, host Shikha Jain, MD, speaks with Komal Jhaveri, MD, about breakthroughs in breast cancer treatment, where the field is evolving with anti-body drug conjugates and more.
How to breathe life into respiratory drug development
We are currently experiencing a renaissance in the treatment landscape for respiratory disease, but we can do better.
Q&A: AI-developed algorithms could change chronic cough monitoring
In November, all but one of the members of the FDA’s Pulmonary-Allergy Drugs Advisory Committee voted against recommending the approval of gefapixant for adults with refractory or unexplained chronic cough.